William Newsome has joined Blueshift Biotechnologies as director of sales and commercial development, Blueshift said last week.
Newsome joins Blueshift from DiscoverX, where he worked to form assay development collaborations within pharma, Blueshift said. He has also held positions at Harvard, Pfizer, and Stratagene.
Qiagen said this week that Douglas Liu has joined the company as vice president of global operations. Liu will oversee all of Qiagen's operations including manufacturing, quality, logistics, and infrastructure.
Liu most recently was head of operations for nucleic acid diagnostics in the US for Bayer Healthcare, and also worked in strategic planning and consulting for Bayer AG, Qiagen said. Before his time at Bayer, he held positions at Abbott Diagnostics and Chiron Diagnostics.
Sigma-Aldrich announced several internal management changes in connection with its recent reorganization:
Shaf Yousaf, vice president of corporate R&D and biotechnology marketing, will become president of the firm's new Biotech unit.
David Julien, most recently president of Sigma's biotechnology business, was named president of the new Specialties unit.
Gilles Cottier, vice president of sales at Sigma, was appointed president of the new Essentials unit.
The firm's SAFC business unit will continue to be led by Frank Wicks, who has served as its president since January 2003.
Ambion last week announced the availability of a new line of pre-plated, ready-to-transfect siRNA libraries called Silencer CellReady siRNA Libraries.
Each pre-defined set includes three individual siRNAs per target plated in the ideal amount for use in a single RNAi screen in human cells, Ambion said. The siRNAs in the libraries were designed by Ambion partner Cenix BioScience, and produced in Ambion's high-throughput manufacturing facility.
Details about the Silencer CellReady siRNA libraries can be found on the company's website at www.ambion.com/info/cellready.